360 Stem Cell & Regenerative Medicine Newsletter- May 7, 2015

 weSRCH's Best of the Internet Award

360 Stem Cell & Regenerative Medicine Newsletter - May 7, 2015

Featured Video: TIME Exclusive! Meet the World’s First Baby Born With an Assist from Stem Cells

“This newborn is the first baby in the world born using a breakthrough IVF treatment. Doctors in Canada have begun a new chapter in medical history, delivering the first in a wave of babies expected to be born this summer through a technique that some experts think can dramatically improve the success rate of in vitro fertilization (IVF). Now 22 days old, Zain Rajani was born through a new method that relies on the discovery that women have, in their own ovaries, a possible solution to infertility caused by poor egg quality. Pristine stem cells of healthy, yet-to-be developed eggs that can help make a woman’s older eggs act young again.

World Stem Cell Summit

Salk Institute: New “Region-Selective Pluripotent Stem Cells” May Overcome Hurdles for Regenerative Medicine
The Salk team discovered a novel type of pluripotent stem cell whose identity is tied to their location in a developing embryo. This contrasts with stem cells traditionally used in scientific study, which are characterized by their time-related stage of development. The researchers dubbed this new class of cells “region-selective pluripotent stem cells,” or rsPSCs for short. According to lead researcher Dr. Juan Carlos Izpisua Belmonte, "The region-specific cells we found could provide tremendous advantages in the laboratory to study development, evolution and disease, and may offer avenues for generating novel therapies.” The research was published in the journal Nature.

What should we make of this? Well, scientists say using these new cells we could grow whole new human organs in livestock! To understand the context, read the article written by ace biotech journalists, Bradley Fikes and Gary Robbins, of the Union-Tribune. Click here.

The Alliance for Regenerative Medicine (ARM) Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015
The Alliance for Regenerative Medicine (ARM), a leading international organization representing the regenerative medicine and advanced therapies community, released its first-ever quarterly data report, offering an in-depth look at sector trends and metrics from the months January through March 2015. A key highlight: “There were 486 clinical trials underway at the end of first quarter 2015, with 150 in Phase I, 288 in Phase II and 48 in Phase III. More than one third of current clinical trials are focused on oncology and more than one tenth are in the cardiovascular space.”

Wake Forest

ALS News Today: Phase 1 Clinical Trial Shows Safety of Stem-Cell Based Therapy in ALS Patients
In a new study entitled “Phase I Trial of Repeated Intrathecal Autologous Bone Marrow-derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis,” researchers performed a safety study with stem cells based therapy to treat ALS patients and concluded it as a safe and promising therapy. The study reports the results of a Phase 1 Clinical Trial and was published in the journal STEM CELLS Translational Medicine, the official journal of the Regenerative Medicine Foundation.


University of Georgia: Using Pig Skin for Neural Development in Humans
More livestock. “A pig’s skin cells may hold the key to new treatments and cures for devastating human neurological diseases. Researchers from the University of Georgia’s College of Agricultural and Environmental Sciences working in the UGA Regenerative Bioscience Center have discovered a process of turning pig induced pluripotent stem cells into induced neural stem cells. The results, published in Stem Cells and Development and based on the same process that neural stem cells use to develop in humans, allows the team to better understand degenerative neural diseases such as Alzheimer’s disease, Parkinson’s and ALS.” The lead investigator is Dr. Steve Stice, who serves as one of the co-chairs for the upcoming World Stem Cell Summit in Atlanta, December 10-12. Follow the latest Summit updates- big announcements coming soon- at www.worldstemcellsummit.com.


Canada: Industry Collaborations Are Key CCRM Strategy to Drive Commercialization in Regenerative Medicine Field
“In under four years, the Centre for Commercialization of Regenerative Medicine (CCRM) has established an industry consortium of 45 companies, from around the globe, including Big Pharma and Canadian startups, that cover the key sectors in regenerative medicine (RM). These include companies like Canadian success story STEMCELL Technologies, and multinational firms such as GE Healthcare, Pfizer, Amgen, Lonza and Thermo Fisher, that specialize in reagents, devices, therapeutics and cells as tools. To date, CCRM has initiated 12 co-development partnerships with its industry members and more strategic projects are planned for the near future. “ Editor’s note: CCRM maintains one of the most innovative models to advance commercialization.


Harvard Gazette: ‘New Clarity’ Against Alzheimer’s
Sometimes it is more than just stem cells. Could we have a statin for Alzheimer’s? Rudolph Tanzi, the Joseph P. and Rose F. Kennedy Professor of Child Neurology and Mental Retardation at Harvard Medical School, last month was named to Time magazine’s list of the 100 most influential people in the world for his contributions uncovering Alzheimer’s genetic underpinnings. Read this illuminating interview in the Harvard Gazette.


Xconomy: Cellular Dynamics Sale a Windfall For Founders, Execs, & Board Members
360 Editor’s comment: Dr. Jamie Thomson gets $16.9 million- wow! It helps to be smart. I have a feeling he’s still in the lab working every day.

BBC News: Cardiff University (Wales) Scientists in Cancer Breakthrough
“Scientists working on stem cell research at Cardiff University believe they have made a potential breakthrough in combating cancer. Researchers have identified a compound that targets aggressive tumor cells found in breast, pancreas, colon and prostate cancers. The discovery has now been licensed to biotech investors Tiziana Life Sciences.” Read the Cardiff University media release here.

Wake Forest

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute

Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter

About GPI

The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn

Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan

Copyright © 2015 Genetics Policy Institute, All rights reserved.

Domain: Medical
Category: Biology

Recent Newsletters

Linley Newsletter: August 8, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #664 August 8, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

08 August, 2019

Linley Newsletter: August 1, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #663 August 1, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

01 August, 2019

Linley Newsletter: July 25, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #662 July 25, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry

25 July, 2019